1. Home
  2. FSK vs BLCO Comparison

FSK vs BLCO Comparison

Compare FSK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSK
  • BLCO
  • Stock Information
  • Founded
  • FSK 2007
  • BLCO 1853
  • Country
  • FSK United States
  • BLCO Canada
  • Employees
  • FSK N/A
  • BLCO N/A
  • Industry
  • FSK Investment Managers
  • BLCO Ophthalmic Goods
  • Sector
  • FSK Finance
  • BLCO Health Care
  • Exchange
  • FSK Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • FSK 5.4B
  • BLCO 4.9B
  • IPO Year
  • FSK N/A
  • BLCO 2022
  • Fundamental
  • Price
  • FSK $21.32
  • BLCO $13.72
  • Analyst Decision
  • FSK Hold
  • BLCO Hold
  • Analyst Count
  • FSK 7
  • BLCO 12
  • Target Price
  • FSK $20.07
  • BLCO $15.55
  • AVG Volume (30 Days)
  • FSK 1.1M
  • BLCO 825.4K
  • Earning Date
  • FSK 08-06-2025
  • BLCO 07-30-2025
  • Dividend Yield
  • FSK 13.64%
  • BLCO N/A
  • EPS Growth
  • FSK N/A
  • BLCO N/A
  • EPS
  • FSK 1.90
  • BLCO N/A
  • Revenue
  • FSK $1,687,000,000.00
  • BLCO $4,829,000,000.00
  • Revenue This Year
  • FSK N/A
  • BLCO $7.10
  • Revenue Next Year
  • FSK N/A
  • BLCO $5.50
  • P/E Ratio
  • FSK $11.19
  • BLCO N/A
  • Revenue Growth
  • FSK N/A
  • BLCO 11.94
  • 52 Week Low
  • FSK $17.42
  • BLCO $10.45
  • 52 Week High
  • FSK $24.10
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • FSK 43.48
  • BLCO 51.06
  • Support Level
  • FSK $21.97
  • BLCO $13.81
  • Resistance Level
  • FSK $22.68
  • BLCO $14.49
  • Average True Range (ATR)
  • FSK 0.36
  • BLCO 0.50
  • MACD
  • FSK -0.09
  • BLCO -0.05
  • Stochastic Oscillator
  • FSK 8.11
  • BLCO 8.44

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: